A brief report of the status of central nervous system metastasis enrollment criteria for advanced non-small cell lung cancer clinical trials: A review of the clinicaltrials.gov trial registry

Journal of Thoracic Oncology

Volumn 11, Issue 3, 2016, Pages 407-413

  McCoach, Caroline E ^a   Berge, Eamon M ^a   Lu, Xian ^b   Barón, Anna E ^b   Ross Camidge, D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Food Science and Human Nutrition   (United States)

Author keywords

Clinical trial enrollment; Clinicaltrials.gov; CNS metastases; Leptomeningeal disease; NSCLC

Indexed keywords

ADVANCED CANCER; BRAIN METASTASIS; CANCER REGISTRY; CENTRAL NERVOUS SYSTEM INFECTION; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL (TOPIC); HUMAN; LEPTOMENINGEAL DISEASE; MULTIVARIATE ANALYSIS; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; WEB BROWSER; ADOLESCENT; ADULT; AGED; BRAIN TUMOR; FEMALE; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; REGISTER; SECONDARY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; REGISTRIES; YOUNG ADULT;

EID: 84962570476     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.10.024     Document Type: Article

References (16)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385-2394.
3. Fouad MN, Lee JY, Catalano PJ, et al. Enrollment of patients with lung and colorectal cancers onto clinical trials. J Oncol Pract. 2013; 9: e40-e47.
4. Sanchez de Cos J, Sojo Gonzalez MA, Montero MV, Perez Calvo MC, Vicente MJ, Valle MH. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer. 2009; 63: 140-145.
5. Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer. 2004; 45(suppl 2): S253-S257.
6. Lin NU, Lee EQ, Aoyama H, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013; 14: e396-e406.
7. Lin NU, Wefel JS, Lee EQ, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013; 14: e407-e416.
8. International Committee of Medical Journal Editors. Clinical Trial Registration. http: //www.icmje.org/recommendations/browse/publishing-And-editorial-issues/clinical-Trial-registration.html. Accessed July 17, 2015.
9. National Institutes of Health. History, Policies, and Laws https: //www.clinicaltrials.gov/ct2/about-site/history. Accessed July 17, 2015.
10. Subramanian J, Regenbogen T, Nagaraj G, et al. Review of ongoing clinical trials in non-small-cell lung cancer: A status report for 2012 from the ClinicalTrials.gov Web site. J Thorac Oncol. Jul 2013; 8: 860-865.
11. Fisher RA. On the interpretation of c2 from contingency tables, and the calculation of P. J R Stat Soc. 1922; 85: 87-94.
12. Freedman DA. Statistical Models: Theory and Practice. New York, NY: Cambridge University Press; 2009.
13. Goldberg SB, Gettinger SN, Mahajan A, et al. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases [abstract]. J Clin Oncol. 2015; 33(suppl): 8035.
14. Kluger HM, Goldberg SB, Sznol M, et al. Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases [abstract]. J Clin Oncol. 2015; 33(suppl): 9009.
15. Camidge DR. Taking aim at ALK across the blood-brain barrier. J Thorac Oncol. 2013; 8: 389-390.
16. Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015; 16: e270-e278.